Over the past decade, the tumor necrosis factor alfa (TNFα) antagonists have had a profound impact on the management of immune-mediated diseases. These agents, infliximab, etanercept, and adalimumab, have been used in the treatment of adults and children with rheumatoid arthritis, Crohn's disease, and a variety of other related conditions.[1,2] They are effective in reducing inflammation and are typically well tolerated. Both infliximab and etanercept have been approved by the Food and Drug Administration (FDA) for use in children, and it is anticipated that adalimumab will also be approved. This issue of Pediatric Pharmacotherapy will review the pharmacology of the TNFα antagonists and recent studies supporting their use in the treatment of children with immune-mediated diseases.
Pediatr Pharm. 2007;13(8):1-4. © 2007 Children's Medical Center, University of Virginia
Cite this: Tumor Necrosis Factor Alfa Antagonists for Pediatric Immune-Mediated Diseases - Medscape - Aug 01, 2007.